Antibody persistence following meningococcal ACWY conjugate vaccine licensed in the European Union by age group and vaccine

Luo, Weichang; Arkwright, Peter D.; Borrow, Raymond

doi:10.1080/14760584.2020.1800460

Cited by 3 publications

(1 citation statement)

References 48 publications

(113 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the decade since its first approval, MenACWY-CRM has continued its clinical development program and has been licensed in over 60 countries [ 47 ], where over 58 million doses have been distributed. Age indications for MenACWY-CRM have also been expanded and currently range from 2 years onwards in the EU, between 2 months and 55 years in the USA and from 2 months onwards in several other countries, such as Argentina, Brazil, Australia and Saudi Arabia.…”

Section: Menacwy-crm Composition Development and Licensurementioning

confidence: 99%

A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine

García¹,

Abitbol

Pellegrini³

et al. 2021

Infect Dis Ther

View full text Add to dashboard Cite

The quadrivalent A, C, W and Y meningococcal vaccine conjugated to nontoxic mutant of diphtheria toxin (MenACWY-CRM) has been licensed since 2010 for the prevention of invasive meningococcal disease (IMD), an uncommon but life-threatening condition. Here, we summarize the experience accrued with MenACWY-CRM during the first decade since its licensure, by providing an overview of clinical trials investigating the safety, immunogenicity and co-administration of MenACWY-CRM with other vaccines as well as presenting real-world evidence regarding the impact of MenACWY-CRM vaccination on carriage and IMD incidence. MenACWY-CRM has demonstrated an acceptable clinical safety profile across a wide range of age groups; no safety concerns have been reported in special populations, such as immunocompromised infants and toddlers, or pregnant women. MenACWY-CRM has also been proven to be immunogenic in various age groups and geographic settings, and a booster dose has been shown to elicit strong anamnestic responses in all studied populations, irrespective of the vaccine used for priming. With no clinically relevant vaccine interactions reported, MenACWY-CRM is being conveniently integrated into existing vaccination programs for various age and risk groups; this possibility of co-administration helps improving vaccine coverage and streamlining the healthcare process of fighting preventable infectious diseases. Vaccination of adolescents and adults has been proven to reduce nasopharyngeal carriage for serogroups C, W and Y, which is an important element in reducing transmission. Real-world evidence indicates that MenACWY-CRM can reduce IMD incidence even in high-exposure groups. When combined with vaccines against serogroup B meningococci, MenACWY-CRM can offer protection against five of the most common serogroups responsible for IMD, which is an important advantage in the continuously evolving landscape of meningococcal serogroup epidemiology. Supplementary Information The online version contains supplementary material available at 10.1007/s40121-021-00519-2.

show abstract

Section: Menacwy-crm Composition Development and Licensurementioning

confidence: 99%